Clinical Trials on Lung Cancer Non-small Cell Stage IV

Total 9940 results

University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditions

United States
Karen Kelly
Bristol-Myers Squibb; National Cancer Institute (NCI); Transgene

Completed

TG4010 and Nivolumab in Patients With Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Unknown

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage III Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute

Completed

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
University of California, Davis
National Cancer Institute (NCI)

Completed

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Gene Solutions

Recruiting

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

Non Small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage IIIC Non-Small Cell Lung Cancer | Tyrosine Kinase Inhibitors

Vietnam
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology... and other collaborators

Terminated

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer (MARVEL)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States, Canada
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
City of Hope Medical Center
National Cancer Institute (NCI); National Institute of Nursing Research (NINR)

Completed

Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Caregiver | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Psychological Impact of Cancer and Its Treatment

United States
Clifford Hospital, Guangzhou, China

Completed

Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer (VCONSCLC)

Carcinoma, Non-Small-Cell Lung | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Mesothelin Positive

United States
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Assistance Publique - Hôpitaux de Paris
Bristol-Myers Squibb

Terminated

Tumor Mutational Burden in Lung Cancer Patients (MUBULUC)

Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage III | Non-Small Cell Carcinoma of Lung

France
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Adult Solid Neoplasm

United States
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
University of California, San Francisco
AstraZeneca

Active, not recruiting

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Stage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer (PAINT)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Malignant Neoplasm in the Brain | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute

Completed

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Gene Mutation

United States
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage IIIA
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Stage III Lung Adenocarcinoma AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...

United States
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Pharmatech
Sanofi; Genentech, Inc.

Terminated

Phase II Avastin Trial for Stage IIIB/IV NSCLC

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV
Synta Pharmaceuticals Corp.

Completed

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Regione Lombardia

Completed

Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial (ONC-MANILA12)

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

Italy
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
City of Hope Medical Center
OSI Pharmaceuticals

Completed

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Neelesh Sharma MD PhD

Completed

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Institut Català d'Oncologia
Institut d'Investigació Biomèdica de Bellvitge; Asociación Española contra...

Recruiting

Psychosocial eHealth in Advanced Lung Cancer

Lung Cancer | Lung Cancer Stage IV | Lung Cancer, Nonsmall Cell, Stage IIIA | Lung Cancer Non-Small Cell Stage IIIB | Lung Cancer Non-Small Cell Stage III

Spain
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Terminated

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States

Clinical Trials on Lung Cancer Non-small Cell Stage IV

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations